Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]
SEC Accession No. 0001641172-25-011513
Filing Date
2025-05-19
Accepted
2025-05-19 17:19:35
Documents
16
Period of Report
2024-12-31

Document Format Files

Seq Description Document Type Size
1 10-K/A form10-ka.htm   iXBRL 10-K/A 54605
2 EX-31.3 ex31-3.htm EX-31.3 3349
3 EX-31.4 ex31-4.htm EX-31.4 3377
  Complete submission text file 0001641172-25-011513.txt   357809

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE immx-20241231.xsd EX-101.SCH 3440
5 XBRL DEFINITION FILE immx-20241231_def.xml EX-101.DEF 2832
6 XBRL LABEL FILE immx-20241231_lab.xml EX-101.LAB 51288
7 XBRL PRESENTATION FILE immx-20241231_pre.xml EX-101.PRE 34407
18 EXTRACTED XBRL INSTANCE DOCUMENT form10-ka_htm.xml XML 16143
Mailing Address 10573 W. PICO BLVD. #58 LOS ANGELES CA 90064
Business Address 11400 WEST OLYMPIC BLVD. SUITE 200 LOS ANGELES CA 90064 (888) 958-1084
Immix Biopharma, Inc. (Filer) CIK: 0001873835 (see all company filings)

EIN.: 454869378 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-K/A | Act: 34 | File No.: 001-41159 | Film No.: 25965109
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)